Dose-response effects of d-amphetamine on effort-based decision-making and reinforcement learning
- PMID: 32722661
- PMCID: PMC8115674
- DOI: 10.1038/s41386-020-0779-8
Dose-response effects of d-amphetamine on effort-based decision-making and reinforcement learning
Abstract
Effort-related decision-making and reward learning are both dopamine-dependent, but preclinical research suggests they depend on different dopamine signaling dynamics. Therefore, the same dose of a dopaminergic medication could have differential effects on effort for reward vs. reward learning. However, no study has tested how effort and reward learning respond to the same dopaminergic medication within subjects. The current study aimed to test the effect of therapeutic doses of d-amphetamine on effort for reward and reward learning in the same healthy volunteers. Participants (n = 30) completed the Effort Expenditure for Reward Task (EEfRT) measure of effort-related decision-making, and the Probabilistic Reward Task (PRT) measure of reward learning, under placebo and two doses of d-amphetamine (10 mg, and 20 mg). Secondarily, we examined whether the individual characteristics of baseline working memory and willingness to exert effort for reward moderated the effects of d-amphetamine. d-Amphetamine increased willingness to exert effort, particularly at low to intermediate expected values of reward. Computational modeling analyses suggested this was due to decreased effort discounting rather than probability discounting or decision consistency. Both baseline effort and working memory emerged as moderators of this effect, such that d-amphetamine increased effort more in individuals with lower working memory and lower baseline effort, also primarily at low to intermediate expected values of reward. In contrast, d-amphetamine had no significant effect on reward learning. These results have implications for treatment of neuropsychiatric disorders, which may be characterized by multiple underlying reward dysfunctions.
Figures




References
-
- Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148:1474–1486. - PubMed
-
- Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol. 2007;64:1575–1579. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K08 DA040006/DA/NIDA NIH HHS/United States
- F32 DA048542/DA/NIDA NIH HHS/United States
- R01 MH108605/MH/NIMH NIH HHS/United States
- R00 MH102355/MH/NIMH NIH HHS/United States
- R01MH108605/U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
- R00MH105305/U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
- F32 MH115692/MH/NIMH NIH HHS/United States
- LCF/BQ/DI19/11730047/"la Caixa" Foundation (Caixa Foundation)
- F32MH115692/U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
- F32DA048542/U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)
LinkOut - more resources
Full Text Sources